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After successful meetings in 2009 and 2010, an international faculty of
largely immunologists and rheumatologists will gather in Potsdam on
September 22
nd and 23
rd, 2011 to discuss the impact of cytokines in health
and their contributions to autoimmunity in a symposium named after
Shibasaburo Kitasato (1853 - 1931), who worked in Berlin between 1885 and
1892. During this rather short time, he together with Emil von Behring
discovered the causative pathogens of tetanus and diphtheria and
contributed substantially to our basic understanding of the interaction of
the immune system and invading pathogenic microorganisms In keeping
with the tradition of Kitasato, a major theme of the symposium will be the
translation of basic science principles into understanding human disease.
The keynote lecture of the 2011 Kitasato symposium will be delivered by
Antonio Lanzevecchia (Belinzona/Switzerland) who has contributed many
novel insights into understanding of immune regulation and host defense.
His lecture is entitled “Dissecting the human immune response to
pathogens”.
This year’s Kitasato Symposium will be a joint meeting with the Research
Collaborative Consortium (Sonderforschungsbereich) 650 “Cellular
approaches to the suppression of unwanted immune reactions - from bench
to bedside”. As in previous years, the Kitasato symposium will focus on
mechanisms of autoimmunity and tolerance emphasizing the role of
cytokines. A deeper understanding of these aspects and adapyive and
innate immunity has paved the way to innovative therapies for autoimmune
disease within the last decade, especially in rheumatoid arthritis (inhibition
of TNF, IL-1 and IL-6R) and very recently in systemic lupus erythematosus
(BAFF/BLyS blockade).
In specific sessions, the role of tolerance in autoimmunity as well as
transplantation, signaling pathways in cytokine stimulation, the analysis of
new cytokine targets, and the translational of cytokine biology into human
d i s e a s ew i l lb ed i s c u s s e d .T h eS y m p o s ium will especially focus on novel
developments within the last few years with the promise of yielding new
targets for therapy. In addition, insights on disease biology developing
from the clinical use of biologis will be highlighted.
It is the promise of the meeting to provide new perspectives of basic,
translational and clinical research in the field serving the ultimate goal of
improving the treatment of patients. The collection of the individual
contributions is summarized in the following abstract supplement.
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Memory T and B lymphocytes and long lived plasma cells represent a
repository of the antigenic experience of an individual. By analyzing the
specificity and function of these cells we can gain insights into the
human immune response and identify mechanisms of protection and
immunopathology. We have developed methods to dissect the functional
heterogeneity and antigenic repertoire of human T cells, B cells and
plasma cells. These methods are used: i) to identify subsets of effector
and memory T cells with distinct roles in immune surveillance and
protection in different tissues against different classes of pathogens, and
ii) to dissect the relative role of plasma cells and memory B cells in the
antibody response to pathogens and to isolate broadly neutralizing
antibodies. A better understanding of the class and specificity of the
human immune response will be instrumental to guide the design of
effective vaccines.
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The maintenance of tolerance to both self tissues foreign organ grafts
depends on the activity of foxp3
+ regulatory T cells (Treg). We have used
MHC-matched skin grafts as a model system to study how such Treg can
be induced therapeutically and the mechanisms by which they act. Using
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any medium, provided the original work is properly cited.monospecific TCR transgenic mice we have shown that a short treatment
with monoclonal antibodies that block full T cell activation in vivo allows
the targeted tissue to itself induce de novo, antigen specific, foxp3
+ Treg
(iTreg) [1]. We also show that these iTreg are not only concentrated
within the target tissue, but are continuously required to suppress the
activity of primed effector cells also present within the tissue [2]. When
t a k e nt o g e t h e rw i t hp r e v i o u sf i n d ings of linked suppression and
infectious tolerance [3], the evidence suggests that tolerance maintained
by iTreg is dependent on a local, tolerogenic microenviroment within the
tissue. One component of this microenvironment is the induction, by
both innate inflammation and iTreg, of multiple enzymes that consume
essential amino acids, including tryptophan, arginine and valine. Local
amino acid depletion can be sensed by naïve and effector T cells, via the
mammalian target of the immunosuppressive drug rapamycin (mTOR)
pathway, which can synergise with TGFb for the further induction of
foxp3
+ iTreg [4]. TGFb is also able to up-regulate the ectoenzymes CD39
and CD73 both on T cells and antigen presenting cells to catabolise
inflammatory ATP to anti-inflammatory adenosine [5]. Microarray analysis
of tolerated and control skin grafts for patterns of gene expression
associated with the tolerogenic microenvironment confirms that these
mechanisms are preferentially active locally within the tolerated tissues
rather than throughout the systemic lymphoid system. Of particular
interest, these same mechanisms seem to be active in grafted syngeneic
tissues [6], suggesting that iTreg maintained microenvironments are
important for maintaining self tolerance in the face of an inflammatory
insult. The challenge now is how we can exploit appropriate combinations
of T cell blockade, mTOR inhibition and TGFb activation for translation to
the clinic.
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Uncontrolled immune reactions, e.g. in autoimmunity, chronic inflammation
or allergy are a major cause of chronic and partially life-threatening diseases.
Current treatments including those involving biologics largely rely on
unspecific suppression of the effector cells and rarely are able to cure the
disease. The native mechanisms of tolerance, notably those of active
suppression by regulatory cells, have therefore fascinated immunologists
from the beginning on as they promise modulation of the immune system
in an antigen-specific way. However, early attempts to achieve tolerance by
oral immunization or peptide vaccination worked in mouse models, but
hardly were successful in humans. This might have two reasons: a), the
modes of tolerogenic vaccination might not be very efficient, and b), the
abundance of inflammatory effector/memory cells in adult humans might
prevent induction and functioning of regulatory cells.
Our group is presently focusing on the first point and designing novel
modifications of peptide-based vaccines able to induce regulatory cells.
Conjugation of peptides to carrier molecules is one way to improve their in
vivo efficacy in inducing Foxp3+ Tregs. In an EAE model, an improved
protective efficacy can be demonstrated. A second approach is aiming to
target the antigen to the gastrointestinal route which is usually associated
with tolerization rather than effector response. Use of signal molecules
targeting the peptides to epithelial transport mechanisms is presently
explored to improve the efficacy of intestinal vaccination. Finally, we
investigate immunomodulatory substances produced by parasites for a
potential use as tolerogenic adjuvants. While these approaches might help
to improve feasibility of peptide vaccination to induce tolerance, we
assume that treatment of existing autoimmune disease will require a
combination therapy which incorporates elimination of inflammatory
effector cells or suppression of their activity.
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After exposure to alloantigen in vivo and in vitro, alloantigen reactive
immunoregulatory activity is enriched in a population of CD4
+ T cells that
express high levels of CD25, the a chain of the interleukin-2 receptor,
and the transcription factor FOXP3. In vivo, common mechanisms
underpin the activity of CD25
+CD4
+ Treg in adult hosts. We identified a
unique role for IFNg in the functional activity of CD25
+CD4
+ alloantigen
reactive Treg during the development of operational tolerance to donor
alloantigens in vivo that is consistent with observations showing that
tolerance to alloantigens cannot be induced in the absence of IFNg [1]. In
order to provide proof of concept data for translation of findings in
preclinical models to the bedside, we have demonstrated that human
regulatory T cells expanded ex vivo c a np r o t e c th u m a na l l o g r a f t s( s k i n
and vessels) from rejection [2,3].
The identification and characterisation of Treg that can control immune
responsiveness to alloantigens has opened up exciting opportunities for
new therapies in transplantation.
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Achieving tolerance or drug minimization after transplantation and thus
preventing permanent immunosuppression with all the known severe
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the last 20 years major progress has been made in understanding
the tolerance underlying mechanisms and develop therapeutic strategies
in small animal models. However, such knowledge could be rarely
translated into the development of successful new therapeutic
approaches in clinical transplantation. The success is limited by clinical
challenges which are not present in our clean animal facilities such as
1) heterologous immunity - pathogen-specific memory T and B cells
recognize alloantigens and boost the immune response towards the
allograft, 2) pre-sensitization of recipients - presence of allo-specific
memory T and B cells which are inert to most known therapeutic
regimens. Thus we know now that we need more personalized treatment
strategies according to the patient’s immune reactivity. Such a strategy
should combine three important aspects: i) an improved immune
monitoring; ii) treatment which target memory cells and iii) strategies to
reinforce regulation.
We have established preclinical transplant models with preformed allo-
reactive or pathogen-specific memory T cells in which we compare
effectiveness of different treatment approaches combining depletional
with regulatory approaches.
Furthermore, we have performed a DNA microarray screen on samples of
transplant patients and identified surface molecules specifically expressed
by naïve, central memory, effector memory or terminal differentiated
effector memory (TEMRA) T cells. Using this approach we hope to develop
antibodies, which specifically deplete effector memory and TEMRA cells
but spare naïve and central memory T cells. Such a treatment will be
associated with less side effects e.g. infectious complications as compared
to global depletion of T and B cells.
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Haploidentical transplantation, with extensive T cell depletion to prevent
GvHD, is associated with a high incidence of infection-related deaths. The
key challenge is to improve immune recovery with allogeneic donor T cells
without triggering GvHD. As T regulatory cells (Tregs) controlled GvHD in
preclinical studies, the present phase I/II clinical trial evaluated the impact of
early infusion of donor CD4/CD25+ Tregs, followed by an inoculum of donor
mature T cells (Tcons) and positively immunoselected CD34+ cells. Twenty-
eight patients (median age 41, range 21-60) were enrolled from September
2008 onwards; 22 had AML (10 in CR1 at high risk, 10 in ≥C R 2a n d2i n
relapse), 5 had ALL (4 in CR1; 1 in relapse) and 1 had high grade NHL in
relapse. Conditioning was: 8 Gy single fraction TBI, thiotepa (4 mg/kg × 2),
fludarabine (40 mg/m
2 × 5), cyclophosphamide (35 mg/kg × 2). All patients
received immunoselected Tregs (CliniMACS, Miltenyi Biotec) (23/28 2 ×
10
6/kg bw; 5/28 4 × 10
6/kg bw) and 4 days later positively immunoselected
CD34+ cells (median 8.2 × 10
6/kg bw, range 5.0-19.1) together with Tcons
(4/28 0.5 × 10
6/ k gb w ;1 7 / 2 81×1 0
6/kg bw; 5/28 2 × 10
6/kg bw; 2/28 did
not receive Tcons). CD4/CD25
+ Tregs (purity 92.7 ± 2.1) consisted of 33.6% ±
13.1 CD25
high; 58.1% ± 6.6 CD25
int; 5.8% ± 2.5 CD25
low; 65.7% ± 11.8 FoxP3;
17.4% ± 7.2 CD127 (mean ± SD). No GvHD prophylaxis was administered.
26/28 patients engrafted. No GvHD developed in 24/26 patients, 2 developed
≥ grade II GvHD. Ten patients died (3 VOD, 2 fungal pneumonia, 1 bacterial
sepsis, 1 CNS aspergillosis, 1 systemic toxoplasmosis, 1 adenoviral infection,
1 MOF). CD4 and CD8 counts reached, respectively, 50/μL medianly on days
34 (range 19-63 days) and 24 (range 15-87); 100/μLm e d i a n l yo nd a y s4 7
(range 28-100 days) and 34 (range 19-95); 200/μL on days 70 (range 41-146
days) and 61 (range 21-95). A wide T-cell repertoire developed rapidly with
high frequencies of specific CD4+ and CD8+ for opportunistic pathogens.
Episodes of CMV reactivation were significantly fewer than after our
“standard haplo” transplants. In KIR ligand-mismatched transplants, speed of
NK cell reconstitution/maturation and size of donor vs recipient alloreactive
NK cell repertoires were preserved. In conclusion, in the setting of
haploidentical transplantation infusion of Tregs makes administration of a
high dose of T cells feasible for the first time. This strategy provides a long-
term protection from GvHD and robust immune reconstitution.
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Background: Effector T cells play an important role in the pathogenesis
of lupus. As recently shown in murine lupus, they contribute to tissue
damage and glomerulonephritis.
Methods: The role of naturally occurring regulatory T cells (Treg) and of
IL-2 was studied in vitro and in vivo by using flow cytometry and the
NZB/W lupus mouse model.
Results: In healthy individuals as well as in young lupus prone mice without
any signs of the disease, effector T cells are tightly controlled by naturally
occurring regulatory T cells (Treg) that can be shown by different approaches:
1. After depletion of Treg cells by anti-CD25 therapy, murine lupus is strongly
accelerated. 2. After passive transfer of Treg (CD4+CD25+ T cells consisting of
95% FoxP3+ T cells), murine lupus improved reflected by reduced proteinuria
and increased survival compared to control mice [1]. 3. In vitro depletion of
Treg lead to better detection of autoantigen-specific effector T cells with
frequencies above the detection limit for flow cytometry. The frequency of
autoangien-specific T cells correlate with the disease activity in human and
murine lupus. The control of effector T cells by Treg cells can be also used for
studying the phenotype of effector T cell and their function at an
autoantigen-specific level. However; as shown in the murine NZB/W lupus
model, there is a progressive loss of Treg/Tcon homeostasis during lupus
development in different compartments with a progressive Treg deficiency. In
lupus mice with proteinuria, the phenotype of effector T cells is very similar to
the T cell phenotype obtained in IL-2 deficient mice. As known from the
literature, IL-2 levels are decreased in SLE patients. According to the
characteristics of Treg, they are more sensitive to IL-2 deficiency. Supporting
this, addition of IL-2 resulted in a dominant proliferation of Treg cells. In
murine lupus, IL-2 improved survival and decreased proteinuria in diseased
NZB/W mice.
Conclusions: O u rd a t as u p p o r tt h ep o s s i b l er o l eo fT r e ga n do fI L - 2
supplementation in lupus therapy. Further studies are underway to
evaluate IL-2 supplementation and its effects on immune cells and
disease symptoms in lupus.
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By definition, adipo(cyto)kines are cytokine-like mediators produced mainly
by adipose tissue. In the human body, they participate in regulating a
variety of physiological functions related to energy metabolism [1] and
inflammation [2]. Increased or decreased adipokine levels are associated
with autoimmune diseases including diabetes mellitus type 1 (DMT1) [3],
rheumatoid arthritis (RA) [4,5], ankylosing spondylitis (AS) [6], systemic
sclerosis (SSc) [7], systemic lupus erythematosus (SLE) [8] and Behçet’s
disease [9-12].
In vitro data suggest that adipokines may contribute to the progression of
RA as they are potent inducers of proinflammatory cytokines, chemokines
and matrix metalloproteinases (MMP) in RA effector cells [13-16].
SSc also appears to be associated with adipokines. Contrary to RA, in which
substantial intraarticular degradation of extracellular matrix occurs, SSc is
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models of fibrosis point towards a dual role of the adipokine adiponectin
as presented by numerous groups at the EULAR congress in London,
specifically an antifibrotic effect in later stages of SSc and a profibrotic
effect in earlier stages, which appears to be induced by proinflammatory
cytokines. Likewise, leptin is involved in the development of liver fibrosis
[17-19].
So far, no or only little functional information is available regarding the
role of adipokines in other autoimmune diseases. Serum level and clinical
correlation analyses, however, suggest an association with adipokines.
In AS, elevated resistin serum levels have been found, while adiponectin
levels remained unchanged [6,20]. On the other hand, leptin is discussed
controversially in AS. Serum levels were decreased in AS according to two
studies [20,21], while they were increased according to another [22]. Also,
while correlations of leptin with parameters of inflammation (C-reactive
protein, IL-6) and disease activity (Bath Ankylosing Spondylitis Disease
Activity Index) have been found by Park et al. [22], no such correlations
could be found by Toussirout et al. [20]. Interestingly, peripheral blood
mononuclear cells (PBMC) from AS patients express and secrete more
leptin, IL-6 and TNF-a than PBMC from control subjects. Additionally,
stimulation of PBMC from AS patients with exogenous leptin led to a
significantly increased IL-6 and TNF-a production [23]. Hence, leptin might
be involved in the pathogenesis of AS.
In SLE, resistin, for example, has been shown to be associated with
general inflammation and bone loss, suggesting a proinflammatory and
disease-promoting function [24].
However, the exact role of adipokines especially in SSc, AS and SLE is still
unclear and will require further investigation. Also, further research is
warranted to show whether adipokines may represent potential
therapeutic targets in this diseases.
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Members of a subfamily of the type 1 four-helix-bundle cytokines with
receptors sharing the common gamma (cg) chain including IL-2, IL-4, IL-7,
IL-9, IL-15, and IL-21 have distinct activities on the differentiation of effector,
memory, and regulatory T cells [1,2]. Furthermore, IL-2, IL-4, and IL-21 serve
distinct roles in control of B cell development and differentiation to
antibody producing cells. We and others recently reported that both IL-2
and IL-21 are essential for maintenance of CD8 T cells and control of chronic
viral infection, while both cytokines are dispensable for expansion and
contraction of CD8 T cells during acute and resolved viral infection [3-7].
While IL-21 has been implicated in cross-regulation of Th17 cells and
inducible regulatory T cells (Treg) in vitro, development of Th17 and Treg
cells and consequently organ-related autoimmune disease remain
unaffected in IL-21R-deficient mice in vivo [8,9]. In contrast, we now found
that IL-21 can potently inhibit proliferation and function of inducible and
natural Treg cells in models of T cell transfer colitis, viral infection, and
asthma. Increased numbers of Tregs in IL-21R-deficient mice offer an
explanation for suppression of Th2-mediated asthma and susceptibility to
chronic viral infection described in the knockout mice [5,10].
Furthermore, the importance of IL-21 for B cell and antibody responses
has been well established. Recently, it has been suggested that IL-21 is
crucial for development of T follicular helper cells (Tfh) and defective B
cell responses in IL-21R-deficient mice are due to the absence of Tfh cells.
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responses were severely impaired in mice that lack IL-21R specifically
on B cells suggesting that IL-21 regulates germinal center responses in a
B cell intrinsic manner [11]. In addition, we have shown that requirement
of IL-21 for a B cell response is overcome by immunization with
particulate antigens containing TLR7/8 ligands (such as viral RNS). These
data demonstrate that innate pathogen patterns (PAMPs) and Th cell
derived signals co-operate in the induction of optimal IgG responses.
Interestingly, in contrast to follicular B cell responses, IL-21 has been
shown to negatively regulate marginal zone (MZ) B-cell survival and
antibody production to Streptococous pneumonia [12].
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Cytokine receptors exist in membrane bound and soluble form. While
most soluble receptors are antagonists, some soluble receptors are
agonists like soluble receptors of the gp130 cytokine family. In vivo,t h e
IL-6/soluble IL-6R complex stimulates several types of target cells not
stimulated by IL-6 alone, since they do not express the membrane bound
IL-6R. This process has been named trans-signaling [1].
We have shown that soluble gp130 is the natural inhibitor of IL-6/soluble
IL-6R complex responses. The recombinant soluble gp130 protein is a
molecular tool to discriminate between gp130 responses via membrane
bound and soluble IL-6R responses. We have constructed a fusion of
soluble gp130 and the Fc portion of human IgG1. This sgp130Fc protein
proved to be efficient in blocking responses via the IL-6/soluble IL-6R
complex without affecting IL-6 responses, which are mediated via the
membrane bound IL-6R [1].
The soluble IL-6R is mostly generated by proteolysis of the IL-6R
transmembrane protein. Shedding of the IL-6R is mediated by the
metalloprotease ADAM17, which is also responsible for the cleavage of
TNFa and ligands of the EGF-R. Consequently, activation of ADAM17 has
different effects on the activation of the immune response as well as on
induction of regenerative responses [2,3].
Interestingly, depending on the animal model used, global blockade of IL-6
signaling by neutralizing monoclonal antibodies and selective blockade of
IL-6 trans-signaling can lead to different consequences. We could recently
show that inhibition of IL-6 trans-signaling was beneficial in a caecum
ligation puncture model whereas global IL-6 blockade showed no benefit
in survival of the animals [4]. In contrast, in a sepsis model induced by a
bolus injection of LPS, both, global blockade of IL-6 signaling by
neutralizing monoclonal antibodies and selective blockade of IL-6 trans-
signaling proved effective in preventing the death of the animals [5]. Also
various infection models suggest a different outcome of global blockade of
IL-6 as compared to selective IL-6 trans-signaling inhibition.
We could show that the extent of IL-6 trans-signaling in chronic
inflammatory diseases and cancer is controlled by the soluble IL-6R. Using
the sgp130Fc protein or sgp130Fc transgenic mice we demonstrate that in
several chronic inflammatory diseases and cancers including inflammatory
bowel disease, peritonitis, rheumatoid arthritis, colon cancer, ovarian
cancer and pancreatic cancer, that IL-6 trans-signaling via the soluble IL-6R
is a crucial step in the development and the progression of the disease.
Therefore, sgp130Fc is a novel therapeutic agent for the treatment of
chronic inflammatory diseases and cancer [1,6-8].
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Imprinting of T helper lymphocytes for the reexpression of cytokines is
crucial for protection against recurring pathogens but also can be a driving
force of chronic inflammation. Th1 and Th17 cells are distinct lineages
of proinflammatory effector/memory cells, imprinted for reexpression of
interferon-g (IFN-g) and interleukin-17 (IL-17), by upregulated expression of
the transcription factors T-bet and RORgt, respectively. Imprinting here
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Page 5 of 7means that while expression of the cytokine genes upon primary
instruction requires signals from both, the T cell receptor and receptors for
instructing cytokines, reexpression requires only T cell receptor signaling in
reactivated effector/memory T cells. Interleukin-12 (IL-12) and IFN-g are
essential instruction signals for the differentiation of Th1 cells and the
imprinting of the Ifng gene. In activated naïve T cells, IFN-g induces the
central Th1 transcription factor T-bet, while T-bet induces the expression of
IFN-g, in a positive, T cell receptor dependent feedback loop polarizing the
T cell into Th1 differentiation. At this time, expression of the IL-12 receptor
b2 chain (IL12Rb2) is repressed by T cell receptor signaling. After TCR
signaling has ceased, i.e. the antigen is eliminated, the IL12Rb2 chain is
expressed and IL-12 triggers a second wave of T-bet expression. This “late”
T-bet expression coincides with expression of the transcription factors Hlx
and Runx3, and it is required for imprinting of Th1 cells for the
reexpression of IFN-g. The signals required for Th17 differentiation and
imprinting are less clearly defined. While signals such as TGF-b and IL-6
lead to the differentiation of IL-17 expressing cell in vitro, such cells fail to
reexpress IL-17 in the absence of these instructive signals. In contrast,
in vivo generated Th17 cells, have a stable memory for reexpression of
IL-17 in vitro, upon restimulation by antigen. Such cells are refractory to
Th1 or Th2 polarizing signals. Th cells coexpressing IFN-g and IL-17 have
been observed in vivo. Ex vivo isolated Th17 cells can be converted into
Th1+17 cells by combined IFN-g and IL-12 signaling. IFN-g is required to
upregulate expression of the IL12Rb2 chain, and IL-12 for Th1
differentiation. These Th1+17 cells stably coexpress RORgta n dT - b e to n
the single cell level, and are imprinted for reexpression of both IFN-g and
IL-17. Thus, for T lymphocytes, polarization and imprinting of inflammatory
responses is regulated by dynamic interaction of IFN-g and IL-12, and
regulation of expression of the IL-12 receptor.
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A hallmark of immunity is the production of a multi-faceted array of
inflammatory cytokines that exerts decisive influence on innate and
adaptive immune responses. The importance oft h e s em e d i a t o r so f
intercellular communication in autoimmunity is illustrated by the beneficial
effects resulting from blockade of single cytokines such as TNF or IL-6 in
these diseases. B lymphocytes can also play pathogenic roles during
autoimmune disease because B cell depletion often led to amelioration of
disease in patients treated with rituximab [1]. The pathogenic functions of
B cells during autoimmune diseases are poorly understood. They might
involve autoantibody production, yet the beneficial effects resulting from
the depletion of B cells usually preceded reduction in autoantibody titers
[2]. We recently demonstrated that the pathogenic activities of B cells
during experimental autoimmune encephalomyelitis (EAE), the primary
animal model for multiple sclerosis (MS), were largely mediated through
provision of inflammatory cytokines. B cells from MS patients also
produced enhanced amounts of inflammatory cytokines, compared to B
cells from healthy individuals, and this abnormality was corrected through
B cell depletion i.e. B cells returning at 1 year after rituximab treatment
showed a normalized cytokine response. Inflammatory processes are
usually balanced by counter-regulatory circuits involving anti-inflammatory
cytokines such as interleukin (IL)-10 [3,4]. We previously demonstrated that
IL-10 production by B lymphocytes played a determinant role for the
resolution of EAE [5]. Accordingly, IL-10 might provide a powerful means
for controlling pathogenic immune reactions. However, administration of
IL-10 into patients achieved little beneficial effects in the clinic, asking for a
better understanding of the immunosuppressive biology of this molecule.
To this end, we pursued the characterization of IL-10-producing B cells in a
model of infection by the intracellular bacterial pathogen Salmonella
typhimurium. Using a novel strain of IL-10.eGFP knock-in mice to facilitate
the tracking of these cells, we could identify IL-10 producing B cells
already within 24 hours after infection in spleen, and demonstrated that all
IL-10
+ B cells expressed the cell surface receptor CD138, which is a
distinctive marker of antibody secreting cells [6,7]. IL-10 expression was
undetectable in other cell types such as dendritic cells, macrophages, or
T cells at this stage, implying that plasmablasts were the first producers of
IL-10 during immune reactions. These data suggest that IL-10 might be
needed at a very early stage of immune reactions to be suppressive.
Collectively, our data showed that B cells have a dual role during
autoimmune diseases, acting both as drivers and regulators of
pathogenesis, and identified cytokine production as core mechanisms in
these complex functions.
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The interleukin-1 (IL-1) family of ligands has 11 members of which most
are proinflammatory. The receptors, signaling pathways, and functions of
the classical family members (IL-1a,I L - 1 b and IL-18) have been studied
extensively. However, knowledge of Interleukin-37 (IL-37/IL-1F7), which
was first identified by in silico research in 2000 remains limited.
IL-37 shares critical amino acid residues with IL-18 and binds to the IL-18-
binding protein enhancing its ability to inhibit IL-18-induced interferon-g.
Data suggest that IL-37 also binds to the IL-18Ra and, for its anti-
inflammatory properties, likely recruits an accessory receptor chain with
inhibitory properties, such as the single Ig IL-1 related receptor. We recently
reported that overexpression of IL-37 in cells of monocytic or epithelial
origin almost completely abolishes the production of proinflammatory
cytokines as IL-1a/b, TNFa, IL-6 and IL-8 in response to TLR-ligands or IL-1b.
Anti-inflammatory cytokines were unaffected. Vice versa, functional
knockdown of IL-37 in primary human cells by siRNA increased the
production of proinflammatory cytokines. IL-37tg mice are protected against
LPS-induced shock. Thus IL-37 is a fundamental inhibitor of innate immune
responses.
IL-37 protein is expressed in human monocytes and upregulated by LPS.
Similarly to IL-1a and IL-33, IL-37 is expressed intracellularly and
translocates to the nucleus upon cell stimulation in a caspase-1
dependent manner. IL-37 interacts inside the cell with Smad3 and
inflammation in IL-37tg mice is increased when endogenous Smad3 is
depleted. IL-37 is also secreted in the supernatant of stimulated
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extracellular functionality of IL-37 is still elusive.
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The prototypic autoimmune disease, systemic lupus erythematosus (SLE), is
known to be associated with polyclonal B cell activation [1]. A number of
cytokines play essential roles in driving or supporting B cell responses, and
are, therefore, candidate targets for controlling the B cell activity in SLE.
Among these cytokines are IL-6, IL-21 and BAFF/BLyS. IL-6 is a pleiotropic
cytokine with effects on a number of cell types, including B cells, where it
plays as essential role in plasma cell differentiation and survival. Blocking
IL-6 activity with tocilizumab is approved for treatment of rheumatoid
arthritis and preliminary data suggest that it might also be effective in the
treatment of SLE [2]. Importantly, treatment of SLE is associated with a
decline in anti-DNA antibodies and also a decrease in the frequency of
circulating plasma cells, suggesting that at least part of its action relates to
an impact on terminal differentiation of B cells into plasma cells. IL-21 is a
type I cytokine with effects on a number of cell types, including a non-
redundant requirement in B cell activation and differentiation into plasma
cells [3]. Levels of IL-21 are elevated in a number of animal models of
lupus and also in human SLE. Blocking IL-21 is effective in animal models
of lupus, whereas polymorphisms in both the IL-21 gene and in the IL-21
receptor gene are associated with human SLE. Trials of blocking IL-21 in
human SLE have not yet begun. BAFF/BLyS(TNFSF13b) is a TNF family
member that binds to 3 separate receptors and contributes to both naïve
B cell and plasma cell survival [4]. Overexpression of BAFF/BLyS in mice
leads to a lupus-like disorder, whereas blocking this cytokine ameliorates
lupus in mouse models. Clinical trials in human SLE of a blocking
monoclonal antibody, belimumab, have shown moderate clinical benefit
associated with decreases in anti-DNA antibody titers and a decrease in
circulating naïve B cells and plasma cells. These results led to the approval
of this product for the treatment of SLE in the US. The approval of
belimumab for treatment of SLE has confirmed that targeting B cells can
be effective in treating this disease and has provided impetus for the
development of additional B cell-directed therapies aimed at blocking
cytokines involved in B cell survival and/or functional responsiveness.
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